A
14.12
0.05 (0.36%)
| Previous Close | 14.07 |
| Open | 14.00 |
| Volume | 611,350 |
| Avg. Volume (3M) | 1,516,440 |
| Market Cap | 1,550,652,288 |
| Price / Sales | 0.660 |
| Price / Book | 4.98 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | 16,317.06% |
| Diluted EPS (TTM) | -3.10 |
| Quarterly Revenue Growth (YOY) | -99.60% |
| Total Debt/Equity (MRQ) | 0.69% |
| Current Ratio (MRQ) | 12.05 |
| Operating Cash Flow (TTM) | -206.98 M |
| Levered Free Cash Flow (TTM) | -182.62 M |
| Return on Assets (TTM) | -40.72% |
| Return on Equity (TTM) | -83.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amylyx Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.2
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.0 |
| Average | -1.20 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 9.54% |
| % Held by Institutions | 85.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (HC Wainwright & Co., 140.79%) | Buy |
| Median | 21.00 (48.73%) | |
| Low | 19.00 (B of A Securities, 34.56%) | Buy |
| Average | 24.67 (74.72%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 14.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (140.79%) | Buy | 15.05 |
| 10 Feb 2026 | 28.00 (98.30%) | Buy | 14.89 | |
| Stifel | 03 Mar 2026 | 21.00 (48.73%) | Buy | 14.11 |
| B of A Securities | 20 Feb 2026 | 19.00 (34.56%) | Buy | 14.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |